Search

Displaying results 711 - 720 of 10000 in total
  1. Target

    Gastrin-releasing peptide receptor

    go.drugbank.com/bio_entities/BE0012984
    TargetHumans

    Receptor for gastrin-releasing peptide (GRP) (PubMed:1655761).

    Polypeptides: Gastrin-releasing peptide receptorSynonyms: GRP-preferring bombesin receptor
  2. Target

    Leukemia inhibitory factor receptor

    go.drugbank.com/bio_entities/BE0013220
    TargetHumans

    Functions as a membrane-bound signal-transducing subunit either in complex with IL6ST/gp130 or as part of the ciliary neurotrophic factor receptor (CNTFR) complex composed by CNTFR, IL6ST/gp130 and LIFR … initiated either by binding directly to cytokines, such as OSM or LIF or CTF1, or through the binding of other cytokines, like CNTF, CLCF1 or the heterodimeric complex CRLF1-CLCF1 to the non-signaling receptor

    Polypeptides: Leukemia inhibitory factor receptorSynonyms: LIF receptor
  3. Target

    Nuclear receptor ROR-gamma

    go.drugbank.com/bio_entities/BE0013275
    TargetHumans

    Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence.

    Polypeptides: Nuclear receptor ROR-gammaSynonyms: Nuclear receptor RZR-gamma, RAR-related orphan receptor C
  4. Target

    Interleukin-17 receptor C

    go.drugbank.com/bio_entities/BE0017016
    TargetHumans

    Receptor for IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RA (PubMed:16785495). … Receptor for the heterodimer formed by IL17A and IL17B as part of a heterodimeric complex with IL17RA (PubMed:18684971).

    Polypeptides: Interleukin-17 receptor CSynonyms: IL-17 receptor C, Interleukin-17 receptor homolog
  5. Target

    Interleukin-17 receptor E

    go.drugbank.com/bio_entities/BE0017393
    TargetHumans

    Specific functional receptor for IL17C. May be signaling through the NF-kappa-B and MAPK pathways. May require TRAF3IP2 /ACT1 for signaling.

    Polypeptides: Interleukin-17 receptor ESynonyms: IL-17 receptor E
  6. Target

    Lysophosphatidic acid receptor 3

    go.drugbank.com/bio_entities/BE0020529
    TargetHumans

    Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. May play a role in the development of ovarian cancer.

    Polypeptides: Lysophosphatidic acid receptor 3Synonyms: LPA receptor 3, Lysophosphatidic acid receptor Edg-7
  7. Drug

    Ergocalciferol

    go.drugbank.com/drugs/DB00153
    ApprovedInvestigationalNutraceutical

    [T577] The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. … [T580] Ergocalciferol is considered the first vitamin D analog and is differentiated from [cholecalciferol] by the presence of a double bond between C22 and C23 and the presence of a methyl group at

    Synonyms: (3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol, (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-olMixtures: Se-Natal, Swical-energy 3e Age
  8. Drug

    Apraclonidine

    go.drugbank.com/drugs/DB00964
    ApprovedInvestigational

    Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.

    Categories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists
  9. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection. … [A222078] The chief surface target of EBOV particles is the GP<sub>1,2</sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic

  10. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    Pemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. … [L51733] Due to the amino acid substitutions in the Fc region (M435L/N441A), pemivibart has an extended serum half-life.[L51728]